Logo image of VAXX

VAXXINITY INC-A (VAXX) Stock Fundamental Analysis

NASDAQ:VAXX - Nasdaq - US92244V1044 - Common Stock - Currency: USD

0.1111  -0.02 (-15.26%)

After market: 0.1107 0 (-0.36%)

Fundamental Rating

1

Overall VAXX gets a fundamental rating of 1 out of 10. We evaluated VAXX against 571 industry peers in the Biotechnology industry. VAXX may be in some trouble as it scores bad on both profitability and health. VAXX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VAXX had negative earnings in the past year.
In the past year VAXX has reported a negative cash flow from operations.
VAXX had negative earnings in each of the past 5 years.
VAXX had a negative operating cash flow in each of the past 5 years.
VAXX Yearly Net Income VS EBIT VS OCF VS FCFVAXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -128.51%, VAXX is not doing good in the industry: 84.27% of the companies in the same industry are doing better.
With a Return On Equity value of -424.66%, VAXX is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROIC N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VAXX Yearly ROA, ROE, ROICVAXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VAXX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VAXX Yearly Profit, Operating, Gross MarginsVAXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

VAXX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VAXX has a worse debt to assets ratio.
VAXX Yearly Shares OutstandingVAXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VAXX Yearly Total Debt VS Total AssetsVAXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

VAXX has an Altman-Z score of -15.07. This is a bad value and indicates that VAXX is not financially healthy and even has some risk of bankruptcy.
VAXX's Altman-Z score of -15.07 is on the low side compared to the rest of the industry. VAXX is outperformed by 84.10% of its industry peers.
A Debt/Equity ratio of 0.99 indicates that VAXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.99, VAXX is not doing good in the industry: 78.29% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z -15.07
ROIC/WACCN/A
WACCN/A
VAXX Yearly LT Debt VS Equity VS FCFVAXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

VAXX has a Current Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
VAXX's Current ratio of 1.89 is on the low side compared to the rest of the industry. VAXX is outperformed by 76.58% of its industry peers.
VAXX has a Quick Ratio of 1.89. This is a normal value and indicates that VAXX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of VAXX (1.89) is worse than 74.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.89
VAXX Yearly Current Assets VS Current LiabilitesVAXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.07% over the past year.
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VAXX will show a small growth in Earnings Per Share. The EPS will grow by 3.26% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VAXX Yearly Revenue VS EstimatesVAXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
VAXX Yearly EPS VS EstimatesVAXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VAXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VAXX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VAXX Price Earnings VS Forward Price EarningsVAXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VAXX Per share dataVAXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y3.5%

More info and screens

0

5. Dividend

5.1 Amount

VAXX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXXINITY INC-A

NASDAQ:VAXX (5/8/2024, 8:24:57 PM)

After market: 0.1107 0 (-0.36%)

0.1111

-0.02 (-15.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2024-05-13/bmo
Earnings (Next)08-07 2024-08-07/amc
Inst Owners2.07%
Inst Owner Change0%
Ins Owners56.51%
Ins Owner Change0%
Market Cap14.08M
Analysts87.5
Price Target15.3 (13671.38%)
Short Float %0.48%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS0.11
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.51%
ROE -424.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.82%
ROA(5y)-250%
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.89
Altman-Z -15.07
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)89.08%
Cap/Depr(5y)94.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.03%
EPS Next Y17.39%
EPS Next 2Y7.34%
EPS Next 3Y3.5%
EPS Next 5Y3.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.34%
OCF growth 3YN/A
OCF growth 5YN/A